Literature DB >> 3029287

Expression of a provirus of human T cell leukaemia virus type I by DNA transfection.

K Mori, H Sabe, H Siomi, T Iino, A Tanaka, K Takeuchi, K Hirayoshi, M Hatanaka.   

Abstract

We isolated the full length provirus of human T cell leukaemia virus type I (HTLV-I) from MT-2, a lymphoid cell line producing HTLV-I. In three non-lymphoid cell lines (COS7, human osteosarcoma HOS cells, and HeLa) this provirus expressed a trans-acting activity after co-transfection with a recombinant plasmid carrying a bacterial chloramphenicol acetyltransferase gene under the control of a long terminal repeat of HTLV-I provirus. The trans-acting protein p40 was detected by immunoprecipitation in transfected HOS cells. Structural proteins of HTLV-I, the gag and env products, were also formed and processed in the same manner as observed in MT-2 cells. In transfected HeLa cells, the p40 protein was mainly localized in the nucleus, while other structural proteins were detected in the cytoplasm and/or the membrane by indirect immunofluorescence. Syncytium formation was observed in HeLa cells after transfection. These results demonstrated that non-lymphoid cells could produce the major proteins of HTLV-I after DNA transfection of the cloned provirus.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3029287     DOI: 10.1099/0022-1317-68-2-499

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  21 in total

1.  Inhibition of human immunodeficiency virus type 1 Rev function by a Rev mutant which interferes with nuclear/nucleolar localization of Rev.

Authors:  S Kubota; R Furuta; M Maki; M Hatanaka
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

2.  Nucleolar targeting signal of human T-cell leukemia virus type I rex-encoded protein is essential for cytoplasmic accumulation of unspliced viral mRNA.

Authors:  T Nosaka; H Siomi; Y Adachi; M Ishibashi; S Kubota; M Maki; M Hatanaka
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

3.  Processing of gag precursor polyprotein of human T-cell leukemia virus type I by virus-encoded protease.

Authors:  S H Nam; M Kidokoro; H Shida; M Hatanaka
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

4.  Novel internal promoter/enhancer of HTLV-I for Tax expression.

Authors:  T Nosaka; Y Ariumi; M Sakurai; R Takeuchi; M Hatanaka
Journal:  Nucleic Acids Res       Date:  1993-11-11       Impact factor: 16.971

5.  Effects of chimeric mutants of human immunodeficiency virus type 1 Rev and human T-cell leukemia virus type I Rex on nucleolar targeting signals.

Authors:  S Kubota; T Nosaka; B R Cullen; M Maki; M Hatanaka
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

6.  A region of basic amino-acid cluster in HIV-1 Tat protein is essential for trans-acting activity and nucleolar localization.

Authors:  S Endo; S Kubota; H Siomi; A Adachi; S Oroszlan; M Maki; M Hatanaka
Journal:  Virus Genes       Date:  1989-11       Impact factor: 2.332

7.  Two major subgroups of human T-cell leukemia virus-1 in Japan.

Authors:  H Siomi; T Nosaka; T Saida; H Miwa; Y Hinuma; S Shirakawa; N Miyamoto; T Kondo; K Araki; M Ichimaru
Journal:  Virus Genes       Date:  1988-07       Impact factor: 2.332

8.  Overgrowth of human synovial cells driven by the human T cell leukemia virus type I tax gene.

Authors:  T Nakajima; H Aono; T Hasunuma; K Yamamoto; I Maruyama; T Nosaka; M Hatanaka; K Nishioka
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

9.  Virions released from cells transfected with a molecular clone of human T-cell leukemia virus type I give rise to primary and secondary infections of T cells.

Authors:  D Derse; J Mikovits; M Polianova; B K Felber; F Ruscetti
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

10.  Characterization of ribosomal frameshifting for expression of pol gene products of human T-cell leukemia virus type I.

Authors:  S H Nam; T D Copeland; M Hatanaka; S Oroszlan
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.